Published in N Engl J Med on November 03, 2012
Tolvaptan Phase 3 Efficacy and Safety Study in ADPKD (TEMPO3/4) | NCT00428948
Efficacy of Tolvaptan on ADPKD Patients | NCT02729662
Tolvaptan for Patients With Acute Neurological Injuries | NCT02545114
Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease. Ann Intern Med (2013) 3.83
The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial. Clin Exp Nephrol (2015) 2.09
Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med (2014) 1.64
Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease? Nephrol Dial Transplant (2014) 1.55
Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int (2015) 1.50
Novel approach to estimate kidney and cyst volumes using mid-slice magnetic resonance images in polycystic kidney disease. Am J Nephrol (2013) 1.50
Cystine nephrolithiasis. Transl Androl Urol (2014) 1.41
mTORC1-mediated inhibition of polycystin-1 expression drives renal cyst formation in tuberous sclerosis complex. Nat Commun (2016) 1.41
Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol (2013) 1.33
Vasopressin: a novel target for the prevention and retardation of kidney disease? Nat Rev Nephrol (2013) 1.26
Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. J Clin Invest (2014) 1.24
Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol (2014) 1.23
Autosomal recessive polycystic kidney disease: a hepatorenal fibrocystic disorder with pleiotropic effects. Pediatrics (2014) 1.14
Primary cilia in the developing and mature brain. Neuron (2014) 1.11
The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease. Clin Exp Nephrol (2015) 1.07
Lipid, blood pressure and kidney update 2013. Int Urol Nephrol (2014) 1.05
Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database. Drug Saf (2015) 1.02
Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study. Am J Kidney Dis (2013) 1.01
Tolvaptan in autosomal dominant polycystic kidney disease. N Engl J Med (2013) 0.96
Identification of Biomarkers for PKD1 Using Urinary Exosomes. J Am Soc Nephrol (2014) 0.96
Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model. J Am Soc Nephrol (2014) 0.94
Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients. World J Gastroenterol (2014) 0.94
Automatic total kidney volume measurement on follow-up magnetic resonance images to facilitate monitoring of autosomal dominant polycystic kidney disease progression. Nephrol Dial Transplant (2015) 0.94
Decongestion in acute heart failure. Eur J Heart Fail (2014) 0.94
Novel diuretic targets. Am J Physiol Renal Physiol (2013) 0.93
Molecular pathways and therapies in autosomal-dominant polycystic kidney disease. Physiology (Bethesda) (2015) 0.93
Segmentation of individual renal cysts from MR images in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2013) 0.91
Polycystin-1: a master regulator of intersecting cystic pathways. Trends Mol Med (2014) 0.91
Adenylyl cyclase 6 deficiency ameliorates polycystic kidney disease. J Am Soc Nephrol (2013) 0.91
Rationale for early treatment of polycystic kidney disease. Pediatr Nephrol (2014) 0.91
Hyponatremia: A practical approach. Indian J Endocrinol Metab (2014) 0.90
Quality of life of patients with ADPKD-Toranomon PKD QOL study: cross-sectional study. BMC Nephrol (2013) 0.90
Refining Genotype-Phenotype Correlation in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol (2015) 0.90
Molecular diagnosis of autosomal dominant polycystic kidney disease using next-generation sequencing. J Mol Diagn (2013) 0.90
Vasopressin and disruption of calcium signalling in polycystic kidney disease. Nat Rev Nephrol (2015) 0.89
Tolvaptan in autosomal dominant polycystic kidney disease. N Engl J Med (2013) 0.89
Tolvaptan in autosomal dominant polycystic kidney disease. N Engl J Med (2013) 0.89
The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol (2015) 0.88
Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function. Kidney Int (2013) 0.88
Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant (2016) 0.88
Effects of hydration in rats and mice with polycystic kidney disease. Am J Physiol Renal Physiol (2014) 0.87
Tolvaptan in autosomal dominant polycystic kidney disease. N Engl J Med (2013) 0.87
CKD hotspots around the world: where, why and what the lessons are. A CKJ review series. Clin Kidney J (2014) 0.87
Translational nephrology: what translational research is and a bird's-eye view on translational research in nephrology. Clin Kidney J (2015) 0.87
Hypoxia-inducible factor-1α causes renal cyst expansion through calcium-activated chloride secretion. J Am Soc Nephrol (2013) 0.87
Urea channel inhibitors: a new functional class of aquaretics. Kidney Int (2013) 0.86
Fatty Acid Oxidation is Impaired in An Orthologous Mouse Model of Autosomal Dominant Polycystic Kidney Disease. EBioMedicine (2016) 0.86
Acute confusion and ataxia in the emergency department with an unexpected underlying diagnosis. Malawi Med J (2013) 0.86
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial. Clin J Am Soc Nephrol (2016) 0.86
ADAM17 promotes proliferation of collecting duct kidney epithelial cells through ERK activation and increased glycolysis in polycystic kidney disease. Am J Physiol Renal Physiol (2014) 0.85
New treatments for autosomal dominant polycystic kidney disease. Br J Clin Pharmacol (2013) 0.85
Effect of increased water intake on plasma copeptin in patients with chronic kidney disease: results from a pilot randomised controlled trial. BMJ Open (2015) 0.85
Short-Term Tolvaptan Increases Water Intake and Effectively Decreases Urinary Calcium Oxalate, Calcium Phosphate and Uric Acid Supersaturations. J Urol (2015) 0.85
Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients. Clin J Am Soc Nephrol (2014) 0.85
Hyponatremia in patients with heart failure. World J Cardiol (2013) 0.84
Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease. Am J Kidney Dis (2013) 0.84
Tolvaptan in autosomal dominant polycystic kidney disease. N Engl J Med (2013) 0.84
A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease. BMC Nephrol (2015) 0.84
Hyponatremia in cirrhosis: pathophysiology and management. World J Gastroenterol (2015) 0.84
Tolvaptan as a tool in renal physiology. Am J Physiol Renal Physiol (2013) 0.83
The prevalence and epidemiology of genetic renal disease amongst adults with chronic kidney disease in Australia. Orphanet J Rare Dis (2014) 0.83
The cleaved cytoplasmic tail of polycystin-1 regulates Src-dependent STAT3 activation. J Am Soc Nephrol (2014) 0.83
Syndrome of inappropriate antidiuretic hormone secretion and cerebral/renal salt wasting syndrome: similarities and differences. Front Pediatr (2015) 0.83
Novel treatments of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2014) 0.83
Phosphodiesterase 1A modulates cystogenesis in zebrafish. J Am Soc Nephrol (2014) 0.82
A stepwise approach for effective management of chronic pain in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant (2014) 0.82
Smelling the roses and seeing the light: gene therapy for ciliopathies. Trends Biotechnol (2013) 0.82
Current management of autosomal dominant polycystic kidney disease. World J Nephrol (2015) 0.82
Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease. Mayo Clin Proc (2015) 0.82
Hyponatraemia and cirrhosis. Gastroenterol Rep (Oxf) (2014) 0.82
Regulation of nephron water and electrolyte transport by adenylyl cyclases. Am J Physiol Renal Physiol (2014) 0.82
Copeptin is associated with kidney length, renal function, and prevalence of simple cysts in a population-based study. J Am Soc Nephrol (2014) 0.82
Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease. Pediatr Nephrol (2017) 0.82
Roles of mTOR complexes in the kidney: implications for renal disease and transplantation. Nat Rev Nephrol (2016) 0.82
Naringenin inhibits the growth of Dictyostelium and MDCK-derived cysts in a TRPP2 (polycystin-2)-dependent manner. Br J Pharmacol (2014) 0.82
The zebrafish Kupffer's vesicle as a model system for the molecular mechanisms by which the lack of Polycystin-2 leads to stimulation of CFTR. Biol Open (2015) 0.82
Mild Chronic Hyponatremia in the Ambulatory Setting: Significance and Management. Clin J Am Soc Nephrol (2015) 0.81
An emerging molecular understanding and novel targeted treatment approaches in pediatric kidney diseases. Front Pediatr (2014) 0.81
2-Deoxy-d-Glucose Ameliorates PKD Progression. J Am Soc Nephrol (2015) 0.81
Semiautomated Segmentation of Polycystic Kidneys in T2-Weighted MR Images. AJR Am J Roentgenol (2016) 0.81
Rationale, design and objectives of ARegPKD, a European ARPKD registry study. BMC Nephrol (2015) 0.80
Identification of people with autosomal dominant polycystic kidney disease using routine data: a cross sectional study. BMC Nephrol (2014) 0.80
Scattered Deletion of PKD1 in Kidneys Causes a Cystic Snowball Effect and Recapitulates Polycystic Kidney Disease. J Am Soc Nephrol (2014) 0.80
Deciphering physiological role of the mechanosensitive TRPV4 channel in the distal nephron. Am J Physiol Renal Physiol (2014) 0.80
Hypertension in autosomal-dominant polycystic kidney disease (ADPKD). Clin Kidney J (2013) 0.80
From bone abnormalities to mineral metabolism dysregulation in autosomal dominant polycystic kidney disease. Pediatr Nephrol (2013) 0.80
Polycystic kidney disease: Tolvaptan in ADPKD-TEMPO 3:4 trial results. Nat Rev Nephrol (2012) 0.80
The Treatment of Autosomal Dominant Polycystic Kidney Disease. Dtsch Arztebl Int (2015) 0.80
Vasopressin-2 receptor signaling and autosomal dominant polycystic kidney disease: from bench to bedside and back again. J Am Soc Nephrol (2014) 0.79
The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease. Nat Rev Nephrol (2015) 0.79
Hyponatremia and Hepatorenal Syndrome. Gastroenterol Hepatol (N Y) (2015) 0.79
MicroRNAs and Polycystic Kidney Disease. Drug Discov Today Dis Models (2013) 0.79
Low-Osmolar Diet and Adjusted Water Intake for Vasopressin Reduction in Autosomal Dominant Polycystic Kidney Disease: A Pilot Randomized Controlled Trial. Am J Kidney Dis (2016) 0.79
Nephrology research-the past, present and future. Nat Rev Nephrol (2015) 0.79
Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4. Clin J Am Soc Nephrol (2016) 0.78
Safety study of somatostatin analogue octreotide for autosomal dominant polycystic kidney disease in Japan. Clin Exp Nephrol (2014) 0.78
Inhibition of Activin Signaling Slows Progression of Polycystic Kidney Disease. J Am Soc Nephrol (2016) 0.78
Effect of Sodium-Glucose Cotransport Inhibition on Polycystic Kidney Disease Progression in PCK Rats. PLoS One (2015) 0.78
Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors. Toxicol Sci (2016) 0.78
Exploring urinary biomarkers in autosomal dominant polycystic kidney disease. Clin Exp Nephrol (2014) 0.78
Prediction of creatinine clearance from serum creatinine. Nephron (1976) 64.02
Random-effects models for longitudinal data. Biometrics (1982) 54.17
Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med (2006) 32.81
Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med (2006) 10.63
Autosomal dominant polycystic kidney disease. Lancet (2007) 8.55
Volume progression in polycystic kidney disease. N Engl J Med (2006) 7.16
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA (2007) 6.25
Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2010) 5.50
Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med (2010) 4.36
Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med (2003) 3.78
Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet (1994) 3.73
Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol (2010) 3.64
Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med (2008) 3.53
Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol (2010) 3.47
Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med (2004) 3.09
Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol (2005) 2.92
Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2012) 2.78
Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol (2006) 2.77
Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol (2007) 2.71
Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol (2005) 2.66
Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates. Am J Kidney Dis (2010) 2.47
Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol (2010) 2.42
Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2009) 2.33
Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int (2005) 2.32
Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug. Nephrol Dial Transplant (2011) 2.04
Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. Dev Genet (1999) 1.80
OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther (1998) 1.74
Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol (2011) 1.63
Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int (2011) 1.44
Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am J Physiol Renal Physiol (2011) 1.40
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am J Kidney Dis (2011) 1.39
Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther (2011) 1.37
Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort. J Am Soc Nephrol (2006) 1.37
The power to detect differences in average rates of change in longitudinal studies. Stat Med (1990) 1.23
National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med (2003) 23.33
Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet (2010) 18.36
Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med (2006) 10.63
The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int (2010) 9.25
Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med (2013) 7.98
Age and association of kidney measures with mortality and end-stage renal disease. JAMA (2012) 7.20
Volume progression in polycystic kidney disease. N Engl J Med (2006) 7.16
Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA (2012) 6.26
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA (2007) 6.25
Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int (2011) 5.47
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int (2011) 5.25
Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med (2014) 5.01
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87
Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int (2003) 4.84
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA (2007) 4.30
Genetic loci influencing kidney function and chronic kidney disease. Nat Genet (2010) 3.75
Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol (2010) 3.64
Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA (2004) 3.39
Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA (2008) 3.31
Evolving importance of kidney disease: from subspecialty to global health burden. Lancet (2013) 3.30
Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2007) 3.26
Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet (2012) 3.04
Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker. Hypertension (2012) 2.86
Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2012) 2.78
CUBN is a gene locus for albuminuria. J Am Soc Nephrol (2011) 2.70
Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol (2005) 2.66
Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int (2004) 2.55
The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrol Dial Transplant (2006) 2.50
Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int (2010) 2.48
Cubilin is essential for albumin reabsorption in the renal proximal tubule. J Am Soc Nephrol (2010) 2.42
Evaluation of urine biomarkers of kidney injury in polycystic kidney disease. Kidney Int (2012) 2.39
Albuminuria, proteinuria, and novel urine biomarkers as predictors of long-term allograft outcomes in kidney transplant recipients. Am J Kidney Dis (2011) 2.38
Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol (2005) 2.37
Microalbuminuria and risk of venous thromboembolism. JAMA (2009) 2.35
Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J (2013) 2.32
Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int (2003) 2.32
Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem (2004) 2.26
Comparison of different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol (2010) 2.22
Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2006) 2.21
Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol (2013) 2.18
Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J (2009) 2.12
Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. Am J Epidemiol (2008) 2.09
Urinary magnesium excretion and risk of hypertension: the prevention of renal and vascular end-stage disease study. Hypertension (2013) 2.03
High citrate diet delays progression of renal insufficiency in the ClC-5 knockout mouse model of Dent's disease. Kidney Int (2005) 2.02
Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat Genet (2004) 1.96
Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens (2010) 1.90
Urinary creatinine excretion, an indirect measure of muscle mass, is an independent predictor of cardiovascular disease and mortality in the general population. Atherosclerosis (2009) 1.88
Loss of chloride channel ClC-5 impairs endocytosis by defective trafficking of megalin and cubilin in kidney proximal tubules. Proc Natl Acad Sci U S A (2003) 1.87
High-sensitive troponin T and N-terminal pro-B type natriuretic peptide are associated with cardiovascular events despite the cross-sectional association with albuminuria and glomerular filtration rate. Eur Heart J (2012) 1.86
Transcriptional and functional analyses of SLC12A3 mutations: new clues for the pathogenesis of Gitelman syndrome. J Am Soc Nephrol (2007) 1.84
A classification of ductal plate malformations based on distinct pathogenic mechanisms of biliary dysmorphogenesis. Hepatology (2011) 1.84
Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment. Clin J Am Soc Nephrol (2012) 1.78
Association of cognitive function with albuminuria and eGFR in the general population. Clin J Am Soc Nephrol (2011) 1.77
A cluster of mutations in the UMOD gene causes familial juvenile hyperuricemic nephropathy with abnormal expression of uromodulin. J Am Soc Nephrol (2003) 1.77
Progression of coronary artery calcification and thoracic aorta calcification in kidney transplant recipients. Am J Kidney Dis (2011) 1.74
Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation (2003) 1.73
An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int Suppl (2004) 1.71
Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation (2009) 1.69
Sodium excretion and risk of developing coronary heart disease. Circulation (2014) 1.67
Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant (2012) 1.67
Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension (2008) 1.66
Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med (2014) 1.64
Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol (2011) 1.63
Imaging for the prognosis of autosomal dominant polycystic kidney disease. Nat Rev Nephrol (2010) 1.63
Fact or fiction of the epidemic of chronic kidney disease--let us not squabble about estimated GFR only, but also focus on albuminuria. Nephrol Dial Transplant (2008) 1.61
A role for Rhesus factor Rhcg in renal ammonium excretion and male fertility. Nature (2008) 1.61
Association of mild to moderate chronic kidney disease with venous thromboembolism: pooled analysis of five prospective general population cohorts. Circulation (2012) 1.59
The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol (2010) 1.59
G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension. Hypertension (2012) 1.59
Cystic and inherited kidney diseases. Am J Kidney Dis (2003) 1.59
Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome. Kidney Int (2008) 1.58
Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation. Kidney Int (2012) 1.58
Spectrum of mutations in Gitelman syndrome. J Am Soc Nephrol (2011) 1.57
The rediscovery of uromodulin (Tamm-Horsfall protein): from tubulointerstitial nephropathy to chronic kidney disease. Kidney Int (2011) 1.56
Screening for chronic kidney disease: where does Europe go? Clin J Am Soc Nephrol (2008) 1.56
The medicinal use of water in renal disease. Kidney Int (2013) 1.56
Urinary and plasma magnesium and risk of ischemic heart disease. Am J Clin Nutr (2013) 1.54
Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol (2011) 1.54
Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2006) 1.53
Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study. Circ Cardiovasc Genet (2012) 1.52
Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int (2005) 1.51